Cabaletta Bio Stock Performance
| CABA Stock | USD 13.32 0.02 0.15% |
The firm shows a Beta (market volatility) of 2.57, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cabaletta Bio will likely underperform. Cabaletta Bio has an expected return of -0.75%. Please make sure to confirm Cabaletta Bio total risk alpha, potential upside, and the relationship between the standard deviation and maximum drawdown , to decide if Cabaletta Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cabaletta Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental drivers remain somewhat strong which may send shares a bit higher in May 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 2.85 | Five Day Return (8.67) | Year To Date Return (38.18) | Ten Year Return 37 | All Time Return 37 |
1 | Exercise or conversion by Gwendolyn Binder of 11000 shares of Cabaletta Bio subject to Rule 16b-3 | 02/02/2024 |
2 | Jefferies starts Cabaletta Bio stock coverage with Buy, sets 36 target | 02/05/2024 |
3 | Will Cabaletta Bio Inc Outperform the Rest of the Stocks in the Healthcare Sector - InvestorsObserver | 02/29/2024 |
4 | Cramer This REIT Is A Little Too Dicey As For Marathon Digital, Own The Pure - Markets Insider | 03/06/2024 |
5 | Should You Add Cabaletta Bio Inc Stock to Your Portfolio Tuesday - InvestorsObserver | 03/12/2024 |
6 | Cabaletta Bio Target of Unusually Large Options Trading - MarketBeat | 03/19/2024 |
7 | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | 03/21/2024 |
8 | Cabaletta Bio Given New 30.00 Price Target at Citigroup - MarketBeat | 04/04/2024 |
9 | Acquisition by Marda Anup of 135000 shares of Cabaletta Bio at 3.21 subject to Rule 16b-3 | 04/08/2024 |
10 | Acquisition by Henriques Richard C Jr of 22000 shares of Cabaletta Bio subject to Rule 16b-3 | 04/22/2024 |
| Begin Period Cash Flow | 81.6 M |
Cabaletta |
Cabaletta Bio Relative Risk vs. Return Landscape
If you would invest 2,228 in Cabaletta Bio on January 25, 2024 and sell it today you would lose (896.00) from holding Cabaletta Bio or give up 40.22% of portfolio value over 90 days. Cabaletta Bio is currently does not generate positive expected returns and assumes 3.8964% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Cabaletta, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cabaletta Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cabaletta Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cabaletta Bio, and traders can use it to determine the average amount a Cabaletta Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1927
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CABA |
Estimated Market Risk
| 3.9 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.75 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cabaletta Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cabaletta Bio by adding Cabaletta Bio to a well-diversified portfolio.
Cabaletta Bio Fundamentals Growth
Cabaletta Stock prices reflect investors' perceptions of the future prospects and financial health of Cabaletta Bio, and Cabaletta Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cabaletta Stock performance.
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 406.35 M | ||||
| Shares Outstanding | 48.24 M | ||||
| Price To Earning | (3.33) X | ||||
| Price To Book | 3.48 X | ||||
| EBITDA | (73.23 M) | ||||
| Net Income | (67.67 M) | ||||
| Cash And Equivalents | 96.81 M | ||||
| Cash Per Share | 3.34 X | ||||
| Total Debt | 5.02 M | ||||
| Debt To Equity | (3.76) % | ||||
| Current Ratio | 15.22 X | ||||
| Book Value Per Share | 4.94 X | ||||
| Cash Flow From Operations | (53.55 M) | ||||
| Earnings Per Share | (1.65) X | ||||
| Market Capitalization | 642.58 M | ||||
| Total Asset | 253.65 M | ||||
| Retained Earnings | (233.24 M) | ||||
| Working Capital | 228.5 M | ||||
| Current Asset | 30.42 M | ||||
| Current Liabilities | 843.74 K | ||||
About Cabaletta Bio Performance
To evaluate Cabaletta Bio Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Cabaletta Bio generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Cabaletta Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Cabaletta Bio market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Cabaletta's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.00 | 0.00 | |
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.31) | (0.33) | |
| Return On Assets | (0.27) | (0.28) | |
| Return On Equity | (0.29) | (0.27) |
Things to note about Cabaletta Bio performance evaluation
Checking the ongoing alerts about Cabaletta Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cabaletta Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cabaletta Bio generated a negative expected return over the last 90 days | |
| Cabaletta Bio has high historical volatility and very poor performance | |
| Net Loss for the year was (67.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cabaletta Bio currently holds about 96.81 M in cash with (53.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.34. | |
| Cabaletta Bio has a poor financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Henriques Richard C Jr of 22000 shares of Cabaletta Bio subject to Rule 16b-3 |
- Analyzing Cabaletta Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cabaletta Bio's stock is overvalued or undervalued compared to its peers.
- Examining Cabaletta Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cabaletta Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cabaletta Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cabaletta Bio's stock. These opinions can provide insight into Cabaletta Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cabaletta Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For information on how to trade Cabaletta Stock refer to our How to Trade Cabaletta Stock guide.Note that the Cabaletta Bio information on this page should be used as a complementary analysis to other Cabaletta Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Cabaletta Stock analysis
When running Cabaletta Bio's price analysis, check to measure Cabaletta Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cabaletta Bio is operating at the current time. Most of Cabaletta Bio's value examination focuses on studying past and present price action to predict the probability of Cabaletta Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cabaletta Bio's price. Additionally, you may evaluate how the addition of Cabaletta Bio to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Cabaletta Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cabaletta Bio. If investors know Cabaletta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cabaletta Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.65) | Return On Assets (0.25) | Return On Equity (0.40) |
The market value of Cabaletta Bio is measured differently than its book value, which is the value of Cabaletta that is recorded on the company's balance sheet. Investors also form their own opinion of Cabaletta Bio's value that differs from its market value or its book value, called intrinsic value, which is Cabaletta Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cabaletta Bio's market value can be influenced by many factors that don't directly affect Cabaletta Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cabaletta Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cabaletta Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cabaletta Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.